NCT03766581 A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel Status COMPLETED Phase PHASE2
NCT03749018 Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03745807 An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT03744676 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) Status COMPLETED Phase PHASE2
NCT03743766 Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting Status COMPLETED Phase PHASE2
NCT03739788 An Investigational Study to Evaluate Experimental Medication BMS-986165 Given as a Tablet and Solution in Healthy Male Participants Status COMPLETED Phase PHASE1
NCT03739619 Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma Status COMPLETED Phase PHASE1/PHASE2
NCT03732560 A Comparison of Nivolumab-based Treatments in a Real-world PD-L1 Positive Metastatic Melanoma Population in the US Status COMPLETED Phase N/A
NCT03730961 An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic Status COMPLETED Phase PHASE2
NCT03729245 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) Status TERMINATED Phase PHASE3
NCT03728361 Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Status COMPLETED Phase PHASE2
NCT03726281 Nivolumab in Platinum Recurrent or Refractory Metastatic Germ Cell Tumors Status WITHDRAWN Phase PHASE2
NCT03724968 Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression Status TERMINATED Phase PHASE2
NCT03723655 A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM Status COMPLETED Phase PHASE2/PHASE3
NCT03721757 CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Status COMPLETED Phase PHASE2
NCT03719144 Understanding and Improving Anticoagulation Dosing for Patients With Atrial Fibrillation Status COMPLETED Phase N/A
NCT03715946 Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer Status COMPLETED Phase PHASE2
NCT03714022 A Study to Evaluate the Pharmacokinetics of Abatacept Converted From Drug Substance by Two Different Processes Status COMPLETED Phase PHASE1